Cargando…

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score

Adjuvant chemotherapy is beneficial for premenopausal women-and not postmenopausal women-with HR-positive, HER2-negative, early breast cancer with 1-3 lymph nodes and a recurrence score of 0-25, according to updated results from the phase III RxPonder study.

Detalles Bibliográficos
Autor principal:	Jacobson, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Conference Perspectives: Highlights from SABCS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963289/ https://www.ncbi.nlm.nih.gov/pubmed/35348778 http://dx.doi.org/10.1093/oncolo/oyac012

Ejemplares similares

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
por: Jacobson, Anne
Publicado: (2022)

Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

SABCS 2021 Insights on Breast Cancer Research: An Interview with Dr. Laura Spring
por: Jacobson, Anne
Publicado: (2022)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

HR Strategy Forum
por: CERN. Geneva
Publicado: (2009)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
por: Cheng, Ran, et al.
Publicado: (2020)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

HR Presentation - New Contract Policy
por: CERN. Geneva
Publicado: (2009)

The impact of passive recruitment strategies on HR practices.
por: LinkedIn, Connie Gibney
Publicado: (2013)

Antibiotic adjuvants: identification and clinical use
por: Bernal, Patricia, et al.
Publicado: (2013)

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
por: Wang, Haibo, et al.
Publicado: (2022)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
por: Bilani, Nadeem, et al.
Publicado: (2022)

Sinoatrial node pacemaker cells: cardiomyocyte- or neuron-like cells?
por: Zhou, Bin
Publicado: (2021)

Breast Cancer Chemotherapy Can Be Administered Safely During the COVID‐19 Pandemic
Publicado: (2021)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
por: Stabellini, Nickolas, et al.
Publicado: (2023)

Real Nano “Light Vaccine” Will Benefit to COVID-19 Pandemic Control
por: Yang, Jianshe
Publicado: (2021)

Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer
por: Davey, Matthew G., et al.
Publicado: (2022)

Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: in defense of de-escalation
por: Lake, Diana, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Compartmentalized multicellular crosstalk in lymph nodes coordinates the generation of potent cellular and humoral immune responses
por: Poirot, Justine, et al.
Publicado: (2021)

Mechanical nanosurgery approach: assistance to overcome the chemotherapy resistance of glioblastoma
por: Chen, Qi, et al.
Publicado: (2023)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Directed evolution, natural products for cancer chemotherapy, and micro‐biosensing robots
por: Daniels, Craig, et al.
Publicado: (2011)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

Combining TMEM Doorway Score and Mena(Calc) Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients
por: Ye, Xianjun, et al.
Publicado: (2022)

Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
por: de Jongh, Felix E., et al.
Publicado: (2022)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India
por: Parikh, Purvish M., et al.
Publicado: (2021)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

Bamboo nodes show nature's wisdom
por: Cölfen, Helmut
Publicado: (2022)

Clinical internship at the Department of Dermatology, Venereology and Allergology, Medical University of Gdansk
por: Purzycka-Bohdan, Dorota, et al.
Publicado: (2017)

World Digestive Health Day – WDHD Poland 2017 Inflammatory Bowel Diseases – Challenges and Hopes
por: Marlicz, Wojciech
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_srcf9a76d0quljfc8srcp4ofc8